Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you
Mutualfunds logo

JFNCX Janus Henderson Global Life Sciences C

  • Fund
  • JFNCX
  • Price as of: Mar 20, 2019
  • $51.54
  • - $0.42
  • - 0.81%
  • Category
  • Health & Biotech Equities

JFNCX - Profile

Vitals

  • YTD Return 13.6%
  • 3 Yr Annualized Return 13.4%
  • 5 Yr Annualized Return 8.9%
  • Net Assets $3.94 B
  • Holdings in Top 10 30.3%

52 WEEK LOW AND HIGH

$51.54
$42.59
$60.11

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.75%

SALES FEES

  • Front Load N/A
  • Deferred Load 1.00%

BROKERAGE FEES

  • Turnover 46.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

N/A

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 13.6%
  • 3 Yr Annualized Total Return 13.4%
  • 5 Yr Annualized Total Return 8.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.74%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Janus Henderson Global Life Sciences Fund
  • Fund Family Name Janus Henderson
  • Inception Date Jul 06, 2009
  • Shares Outstanding N/A
  • Share Class C
  • Currency USD
  • Domiciled Country United States
  • Manager Andrew Acker

JFNCX - Performance

Return Ranking - Trailing

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 13.6% -14.9% 34.8% 45.54% 3
1 Yr 12.0% -14.8% 24.1% 33.33% 2
3 Yr 13.4% * -7.5% 29.6% 48.15% 3
5 Yr 8.9% * 3.3% 18.7% 45.79% 3
10 Yr 18.2% * 6.1% 22.3% 33.98% 2

* Annualized


Return Ranking - Calendar

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2018 -9.9% -91.9% 19.2% 63.64% 4
2017 20.3% -15.0% 43.9% 41.82% 3
2016 -14.1% -29.8% 33.7% 50.00% 3
2015 -2.0% -20.4% 48.1% 50.00% 3
2014 20.4% -5.8% 31.5% 30.00% 2

Total Return Ranking - Trailing

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD 13.6% -14.9% 34.8% 45.95% 3
1 Yr 11.0% -18.3% 23.8% 26.36% 2
3 Yr 13.4% * -14.2% 29.6% 42.59% 3
5 Yr 8.9% * 2.1% 18.5% 42.06% 3
10 Yr 18.2% * 6.1% 22.3% 31.07% 2

* Annualized


Total Return Ranking - Calendar

Period JFNCX Return Category Return Low Category Return High Rank in Category (%) Quintile
2018 -9.9% -91.9% 19.2% 66.06% 4
2017 20.3% -15.0% 43.9% 44.04% 3
2016 -14.1% -25.1% 100.0% 52.29% 3
2015 8.0% -16.6% 79.8% 49.54% 3
2014 44.2% -5.8% 61.4% 17.43% 1

NAV & Total Return History

JFNCX - Holdings

Filings data as of: Dec 31, 2018

Concentration Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Net Assets 3.94 B 15.5 M 47.6 B 10.71% 2
Number of Holdings 93 28 368 15.18% 3
Net Assets in Top 10 1.05 B 9.61 M 18.5 B 14.29% 2
Weighting of Top 10 30.3% 23.3% 76.6% 37.50% 5

Top 10 Holdings

  1. Eli Lilly and Co 3.12%
  2. AstraZeneca PLC 3.03%
  3. Shire PLC ADR 2.65%
  4. Humana Inc 2.72%
  5. Merck & Co Inc 4.57%
  6. Abbott Laboratories 3.00%
  7. Novartis AG ADR 3.22%
  8. AbbVie Inc 2.79%
  9. UnitedHealth Group Inc 2.60%
  10. Anthem Inc 2.59%

Asset Allocation

Weighting Category Low Category High JFNCX % Rank Quintile
Stocks
97.42% 93.99% 99.99% 22.32% 4
Other
1.83% -4.63% 2.65% 2.68% 1
Cash
0.47% 0.00% 5.84% 29.46% 4
Convertible Bonds
0.28% 0.00% 0.28% 0.89% 1
Preferred Stocks
0.00% 0.00% 2.19% 9.82% 3
Bonds
0.00% 0.00% 4.69% 4.46% 3

Stock Sector Breakdown

Weighting Category Low Category High JFNCX % Rank Quintile
Healthcare
92.58% 14.35% 99.99% 32.14% 5
Financial Services
2.55% 0.00% 3.45% 2.68% 1
Technology
1.50% 0.00% 62.70% 14.29% 3
Utilities
0.00% 0.00% 0.00% 0.89% 3
Real Estate
0.00% 0.00% 2.22% 3.57% 3
Industrials
0.00% 0.00% 10.23% 10.71% 4
Energy
0.00% 0.00% 0.08% 1.79% 3
Communication Services
0.00% 0.00% 0.00% 0.89% 3
Consumer Defense
0.00% 0.00% 1.31% 8.93% 3
Consumer Cyclical
0.00% 0.00% 7.34% 9.82% 3
Basic Materials
0.00% 0.00% 0.53% 2.68% 3

Stock Geographic Breakdown

Weighting Category Low Category High JFNCX % Rank Quintile
US
78.43% 63.03% 99.54% 32.14% 4
Non US
18.99% 0.00% 36.96% 7.14% 2

JFNCX - Expenses

Operational Fees

JFNCX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 1.75% 0.10% 4.31% 26.79% 4
Management Fee 0.64% 0.09% 1.25% 12.50% 2
12b-1 Fee 1.00% 0.00% 1.00% 1.27% 4
Administrative Fee N/A 0.01% 0.40% N/A N/A

Sales Fees

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Front Load N/A 2.50% 5.75% N/A N/A
Deferred Load 1.00% 1.00% 5.00% 12.12% 2

Trading Fees

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JFNCX Fees (% of AUM) Category Low Category High JFNCX Rank Quintile
Turnover 46.00% 0.00% 699.00% 14.29% 4

JFNCX - Distributions

Dividend Yield Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Dividend Yield 0.0% 0.00% 1.15% 46.38% 4

Dividend Distribution Analysis

JFNCX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Dividend Payout History


Net Income Ratio Analysis

JFNCX Category Low Category High JFNCX % Rank Quintile
Net Income Ratio -0.74% -2.15% 1.44% 57.14% 4

Capital Gain Distribution Analysis

JFNCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

JFNCX - Managers

Andrew Acker

Manager

Start Date

May 01, 2007

Tenure

11.84

Tenure Rank

8.8%

Andy Acker is a Portfolio Manager at Janus Henderson Investors, responsible for co-managing the Global Life Sciences strategy, a position he has held since 2007. He also serves as a Research Analyst and leads the firm’s Health Care sector research team. Mr. Acker served as assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst, focusing on companies in the biotechnology and pharmaceutical industries. Prior to Janus, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Mr. Acker received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA from Harvard Business School, graduating with honors. Mr. Acker holds the Chartered Financial Analyst designation.


Ethan Lovell

Manager

Start Date

Jan 12, 2016

Tenure

3.13

Tenure Rank

18.7%

Ethan Lovell is a Portfolio Manager at Janus Henderson Investors, responsible for co-managing the Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries. Before joining Janus in 2007 as a research analyst, Mr. Lovell was a director at ClearBridge Advisors, covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director and later managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University. He has 24 years of financial industry experience. Ethan Lovell is a Portfolio Manager at Janus Henderson Investors, responsible for co-managing the Global Life Sciences strategy, a position he has held since 2016. Prior to this, Mr. Lovell served as assistant portfolio manager on the strategy. He is also a Research Analyst, primarily focusing on the global pharmaceutical and medical device industries. Before joining Janus in 2007 as a research analyst, Mr. Lovell was a director at ClearBridge Advisors, covering companies in the pharmaceutical, biotechnology and medical device industries. Previously, he was managing director and founding partner of Saranac Capital, LP, where he was the health care sector portfolio manager. Mr. Lovell also worked at Salomon Brothers Asset Management as a director and later managing director of the health care team. He began his career at Bear, Stearns & Co. as an equity research analyst covering biotechnology, pharmaceuticals and life science tool companies. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University. He has 24 years of financial industry experience. Mr. Lovell received his bachelor of arts degree, with a double major in chemistry and economics, from Bowdoin College and his MBA from Tulane University.


Tenure Analysis

Category Low

0.1

Category High

21.5

Category Average

9.75

Category Mode

4.2